دورية أكاديمية
أعرض في EDS

Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen.

التفاصيل البيبلوغرافية
العنوان: Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen.
المؤلفون: Lodise TP; Albany College of Pharmacy and Health Sciences, Department of Pharmacy Practice, 106 New Scotland Avenue, Albany, NY, USA., Yucel E; Merck & Co., Inc., 2025 E Scott Ave, Rahway, NJ, USA., Obi EN; Merck & Co., Inc., 2025 E Scott Ave, Rahway, NJ, USA., Watanabe AH; Merck & Co., Inc., 2025 E Scott Ave, Rahway, NJ, USA., Nathanson BH; OptiStatim LLC, 25 Willow Circle, Longmeadow, MA, USA.
المصدر: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Jan 03; Vol. 79 (1), pp. 82-95.
نوع المنشور: Observational Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE
أسماء مطبوعة: Publication: 1997- : London : Oxford University Press
Original Publication: London, New York, Academic Press.
مواضيع طبية MeSH: beta-Lactamase Inhibitors*/adverse effects , Acute Kidney Injury*/chemically induced, Adult ; Humans ; beta-Lactams ; Carbapenems/therapeutic use ; Polymyxins ; Lactams ; Aminoglycosides/adverse effects ; Retrospective Studies ; Incidence ; Anti-Bacterial Agents/pharmacology
مستخلص: Background: Limited comparative data exist on acute kidney injury (AKI) risk and AKI-associated outcomes in hospitalized patients with carbapenem-resistant Gram-negative infections (CR-GNIs) treated with a newer β-lactam/β-lactam-β-lactamase inhibitor (BL/BL-BLI)-, polymyxin (PB)- or aminoglycoside (AG)-containing regimen. This study quantified the risk of AKI and AKI-related outcomes among patients with CR-GNIs treated with a newer BL/BL-BLI-, PB- or AG-containing regimen.
Methods: A multicentre, retrospective, observational study was performed (2016-20). The study included adult hospitalized patients with (i) baseline estimated glomerular filtration rates ≥30 mL/min/1.73 m2; (ii) CR-GN pneumonia, complicated urinary tract infection or bloodstream infection; and (iii) receipt of newer BL/BL-BLI, PG or AG within 7 days of index CR-GN culture for ≥3 days. Outcomes included AKI, in-hospital mortality and hospital costs.
Results: The study included 750 patients and most (48%) received a newer BL/BL-BLI. The median (IQR) treatment duration was 8 (5-11), 5 (4-8) and 7 (4-8) days in the newer BL/BL-BLI group, AG group and PB group, respectively. The PB group had the highest adjusted AKI incidence (95% CI) (PB: 25.1% (15.6%-34.6%) versus AG: 8.9% (5.7%-12.2%) versus newer BL/BL-BLI: 11.9% (8.1%-15.7%); P = 0.001). Patients with AKI had significantly higher in-hospital mortality (AKI: 18.5% versus 'No AKI': 5.6%; P = 0.001) and mean hospital costs (AKI: $49 192 versus 'No AKI': $38,763; P = 0.043).
Conclusions: The AKI incidence was highest among PB patients and patients with AKI had worse outcomes. Healthcare systems should consider minimizing the use of antibiotics that augment AKI risk as a measure to improve outcomes in patients with CR-GNIs.
(© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)
References: Clin Microbiol Infect. 2021 Jan 6;:. (PMID: 33359542)
Antimicrob Agents Chemother. 2014 May;58(5):2740-6. (PMID: 24566187)
J Clin Epidemiol. 1992 Jun;45(6):613-9. (PMID: 1607900)
Intensive Care Med. 2015 Aug;41(8):1411-23. (PMID: 26162677)
BMC Nephrol. 2021 Aug 25;22(1):289. (PMID: 34433442)
BMC Infect Dis. 2017 Apr 17;17(1):279. (PMID: 28415969)
Antimicrob Agents Chemother. 2017 Jul 25;61(8):. (PMID: 28559271)
Crit Care. 2004 Aug;8(4):R204-12. (PMID: 15312219)
Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150. (PMID: 30046639)
Heart Lung. 2020 Sep - Oct;49(5):626-629. (PMID: 32354485)
J Nephrol. 2014 Feb;27(1):73-80. (PMID: 24519865)
Am J Public Health. 2005;95 Suppl 1:S144-50. (PMID: 16030331)
Intensive Care Med. 2023 Feb;49(2):178-190. (PMID: 36764959)
Clin Microbiol Infect. 2021 Feb;27(2):228-235. (PMID: 33130270)
J Antimicrob Chemother. 2015 May;70(5):1552-7. (PMID: 25604744)
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1343-57. (PMID: 23335588)
Pharmacol Res. 2021 Jan;163:105328. (PMID: 33276108)
Infect Dis Ther. 2022 Feb;11(1):187-199. (PMID: 34731456)
Clin J Am Soc Nephrol. 2018 Apr 6;13(4):542-550. (PMID: 29545383)
Am J Med Sci. 2019 Feb;357(2):103-110. (PMID: 30665490)
J Am Soc Nephrol. 2009 Mar;20(3):672-9. (PMID: 19244578)
Ann Intern Med. 2014 Mar 18;160(6):380-8. (PMID: 24723078)
Clin Infect Dis. 2007 Sep 15;45(6):753-60. (PMID: 17712761)
Nephrol Dial Transplant. 2008 Apr;23(4):1203-10. (PMID: 17962378)
BMC Infect Dis. 2013 Aug 19;13:380. (PMID: 23957376)
N Engl J Med. 2019 Feb 21;380(8):791-793. (PMID: 30786196)
Clin Infect Dis. 2022 Aug 25;75(2):187-212. (PMID: 35439291)
Antibiotics (Basel). 2019 Mar 14;8(1):. (PMID: 30875778)
Clin Infect Dis. 2007 Jan 15;44(2):159-77. (PMID: 17173212)
Br J Anaesth. 2013 Jan;110(1):13-20. (PMID: 23171724)
Clin Microbiol Infect. 2022 Apr;28(4):521-547. (PMID: 34923128)
Blood Purif. 2011;31(1-3):159-71. (PMID: 21228585)
Crit Care. 2016 Jul 04;20(1):188. (PMID: 27373891)
Nat Rev Nephrol. 2018 Oct;14(10):607-625. (PMID: 30135570)
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301. (PMID: 27573805)
Antimicrob Agents Chemother. 1999 Jul;43(7):1549-55. (PMID: 10390201)
N Engl J Med. 2019 Feb 21;380(8):729-740. (PMID: 30786187)
Clin Infect Dis. 2016 May 15;62(10):e51-77. (PMID: 27080992)
Med Care. 2007 Oct;45(10 Supl 2):S103-7. (PMID: 17909367)
Infect Drug Resist. 2018 Nov 15;11:2321-2333. (PMID: 30532565)
Crit Care. 2012 Aug 03;16(4):144. (PMID: 22866976)
Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. (PMID: 31400759)
Diagn Microbiol Infect Dis. 2016 Jun;85(2):266-75. (PMID: 27033631)
Clin Kidney J. 2021 Aug 26;15(1):14-20. (PMID: 35035932)
Ann Intern Med. 2006 Aug 15;145(4):247-54. (PMID: 16908915)
J Clin Epidemiol. 2007 Apr;60(4):397-409. (PMID: 17346615)
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. (PMID: 34864936)
Am J Infect Control. 2014 Jun;42(6):612-20. (PMID: 24837111)
BMJ Open. 2018 Jun 19;8(6):e020857. (PMID: 29921683)
JAMA. 2009 Dec 2;302(21):2323-9. (PMID: 19952319)
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3187-92. (PMID: 26926642)
Crit Care Med. 2015 May;43(5):989-95. (PMID: 25746747)
J Am Soc Nephrol. 2005 Nov;16(11):3365-70. (PMID: 16177006)
Clin Infect Dis. 2018 Jan 6;66(2):163-171. (PMID: 29020404)
Clin Microbiol Infect. 2016 Dec;22(12):984-989. (PMID: 27545697)
Nat Rev Nephrol. 2018 Apr;14(4):217-230. (PMID: 29355173)
Kidney Int. 2012 May;81(9):819-25. (PMID: 21975865)
Open Forum Infect Dis. 2020 Jan 13;7(1):ofz536. (PMID: 31951222)
Sci Rep. 2021 Aug 13;11(1):16497. (PMID: 34389761)
Ren Fail. 2023 Dec;45(1):2173498. (PMID: 36728812)
Crit Care Med. 2015 May;43(5):1141-3. (PMID: 25876116)
Lancet Infect Dis. 2018 Mar;18(3):318-327. (PMID: 29276051)
Clin Infect Dis. 2018 Nov 28;67(12):1803-1814. (PMID: 30052813)
Med Care. 2020 Feb;58(2):114-119. (PMID: 31688565)
Intensive Care Med. 2012 Dec;38(12):1930-45. (PMID: 23011531)
Infect Dis Ther. 2018 Dec;7(4):439-455. (PMID: 30270406)
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266. (PMID: 11904577)
Intensive Care Med. 2021 Aug;47(8):835-850. (PMID: 34213593)
Antimicrob Agents Chemother. 1995 Mar;39(3):650-5. (PMID: 7793867)
Emerg Infect Dis. 2014 Jul;20(7):1170-5. (PMID: 24959688)
Open Forum Infect Dis. 2018 Aug 03;5(8):ofy191. (PMID: 30182031)
Clin Infect Dis. 2020 Jul 11;71(2):304-310. (PMID: 31545346)
Pharmacotherapy. 2018 Dec;38(12):1229-1238. (PMID: 30403305)
Med Care. 2012 Dec;50(12):1109-18. (PMID: 22929993)
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1324-31. (PMID: 26195505)
Lancet Infect Dis. 2020 Oct;20(10):1172-1181. (PMID: 32505231)
Pediatr Nephrol. 1997 Dec;11(6):768-72. (PMID: 9438663)
Int J Nephrol. 2021 Dec 20;2021:7795096. (PMID: 34966562)
Open Forum Infect Dis. 2019 Apr 23;6(6):ofz194. (PMID: 31198817)
JAMA. 2020 Apr 21;323(15):1478-1487. (PMID: 32207816)
معلومات مُعتمدة: Merck Sharp & Dohme LLC; Merck & Co., Inc.
المشرفين على المادة: 0 (beta-Lactamase Inhibitors)
0 (beta-Lactams)
0 (Carbapenems)
0 (Polymyxins)
0 (Lactams)
0 (Aminoglycosides)
0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20231114 Date Completed: 20240104 Latest Revision: 20240104
رمز التحديث: 20240104
مُعرف محوري في PubMed: PMC10761276
DOI: 10.1093/jac/dkad351
PMID: 37962080
قاعدة البيانات: MEDLINE
الوصف
تدمد:1460-2091
DOI:10.1093/jac/dkad351